文献速递临床试验与 GCP基础与转化研究

同种异体间充质干细胞作为诱导治疗预防死亡供者肾移植术后移植物功能延迟恢复和急性排斥反应:随机对照试验研究方案

Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-11-16

该研究为前瞻性多中心对照试验方案,拟纳入100例死亡供者肾移植受者,试验组50例在标准诱导治疗基础上术前经外周静脉注射2×10^6/kg人脐带来源间充质干细胞、术中经肾动脉注射5×10^6个细胞,对照组仅接受标准诱导治疗,主要观察术后移植物功能延迟恢复和活检证实的急性排斥反应发生率。

要点

  • 拟纳入100例死亡供者肾移植受者,试验组50例接受脐带来源间充质干细胞联合标准诱导治疗。
  • 试验组术前经外周静脉注射2×10^6/kg人脐带来源间充质干细胞,术中经肾动脉注射5×10^6个细胞。
  • 主要观察指标为术后移植物功能延迟恢复和活检证实的急性排斥反应发生率。

核心结论

  • 该研究旨在明确人脐带来源间充质干细胞在死亡供者肾移植中同时预防移植物功能延迟恢复和急性排斥反应的临床价值,并提供同种异体间充质干细胞能否作为临床可行且安全的诱导治疗的证据。

研究设计与样本

  • 前瞻性多中心对照研究,拟招募100例肾移植受者并分为试验组和对照组,试验组50例。
  • 试验组在标准诱导治疗基础上,术前经外周静脉注射2×10^6/kg人脐带来源间充质干细胞,术中经肾动脉注射5×10^6个细胞。
  • 对照组仅接受标准诱导治疗。

主要发现

  • 将记录并分析术后移植物功能延迟恢复和活检证实的急性排斥反应的发生率。
  • 还将评估基线人口学特征、移植物和受者生存以及其他术后严重并发症,包括复杂性尿路感染、重症肺炎和严重出血。

关键数值与推荐

  • 试验组人脐带来源间充质干细胞剂量:术前经外周静脉注射2×10^6/kg,术中经肾动脉注射5×10^6个细胞。
  • 拟纳入肾移植受者总数n=100,试验组50例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Using kidneys from deceased donors is an available strategy to meet the growing need of grafts. However, higher incidences of delayed graft function (DGF) and acute rejection exert adverse effects on graft outcomes. Since ischemia-reperfusion injury (IRI) and ongoing process of immune response to grafts are the major causes of DGF and acute rejection, the optimal induction intervention should possess capacities of both repairing renal structure injury and suppressing immune response simultaneously. Mesenchymal stem cells (MSCs) with potent anti-inflammatory, regenerative and immune-modulatory properties are considered as a candidate to prevent both DGF and acute rejection in renal transplantation. Previous studies just focused on the safety of autologous MSCs on living-related donor renal transplants, and lack of concomitant controls and the sufficient sample size and source of MSCs. Here, we propose a prospective multicenter controlled study to assess the clinical value of allogeneic MSCs in preventing both DGF and acute rejection simultaneously as induction therapy in deceased-donor renal transplantation. METHODS/DESIGN: Renal allograft recipients (n = 100) will be recruited and divided into trial and control groups, and 50 patients in the trial group will be administered with a dose of 2 × 106 per kilogram human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein injection preoperatively, and a dose of 5 × 106 cells via renal arterial injection during surgery, with standard induction therapy. Incidences of postoperative DGF and biopsy-proved acute rejection (BPAR) will be recorded and analyzed. Additionally, other clinical parameters such as baseline demographics, graft and recipient survival and other severe postoperative complications, including complicated urinary tract infection, severe pneumonia, and severe bleeding, will be also assessed. DISCUSSION: This study will clarify the clinical value of UC-MSCs in preventing DGF and acute rejection simultaneously in deceased-donor renal transplantation, and provide evidence as to whether allogeneic MSCs can be used as clinically feasible and safe induction therapy. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02490020 . Registered on 29 June 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun Q, Hong L, Huang Z, et al. Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29145879. doi:10.1186/s13063-017-2291-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。